Immunocore Holdings plc SEC filings IMCR

Immunocore Holdings plc has 279 filings in SEC EDGAR's recent list, going back to Apr 13, 2016. Its latest annual report, Form ARS, was filed on Apr 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 14, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.

Immunocore Holdings plc SEC filings
Form Description Filed Period
8-K Current report
Regulation FD disclosure
Sep 14, 2026 Sep 14, 2026
8-K Current report
Results of operations
Aug 6, 2026 Aug 6, 2026
8-K Current report
Shareholder vote results
May 27, 2026 May 27, 2026
8-K Current report
Results of operations
May 6, 2026 May 6, 2026
8-K Current report
Results of operations
Feb 25, 2026 Feb 25, 2026
8-K Current report
Officer or director change
Jan 30, 2026 Jan 27, 2026
8-K Current report
Results of operations, Regulation FD disclosure, Other events
Jan 9, 2026 Jan 9, 2026
8-K Current report
Officer or director change
Nov 28, 2025 Nov 26, 2025
8-K Current report
Results of operations
Nov 6, 2025 Nov 6, 2025
8-K Current report
Results of operations
Aug 7, 2025 Aug 7, 2025
8-K Current report
Shareholder vote results
May 15, 2025 May 15, 2025
8-K Current report
Results of operations
May 7, 2025 May 7, 2025
8-K Current report
Other events
Mar 17, 2025 Mar 17, 2025
8-K Current report
Regulation FD disclosure
Mar 10, 2025 Mar 10, 2025
8-K Current report
Results of operations, Officer or director change
Feb 26, 2025 Feb 25, 2025
8-K Current report
Results of operations, Regulation FD disclosure, Other events
Jan 10, 2025 Jan 10, 2025
8-K Current report
Officer or director change, Regulation FD disclosure
Jan 2, 2025 Dec 31, 2024
8-K Current report
Agreement ended
Nov 8, 2024 Nov 8, 2024
8-K Current report
Results of operations
Nov 6, 2024 Nov 6, 2024
8-K Current report
Other events
Sep 16, 2024 Sep 14, 2024
8-K Current report
Officer or director change, Regulation FD disclosure
Aug 29, 2024 Aug 28, 2024
8-K Current report
Results of operations
Aug 8, 2024 Aug 8, 2024
8-K Current report
Regulation FD disclosure
May 31, 2024 May 31, 2024
8-K Current report
Other events
May 30, 2024 May 29, 2024
8-K Current report
Material agreement, Officer or director change
May 28, 2024 May 28, 2024
8-K Current report
Shareholder vote results
May 23, 2024 May 23, 2024
8-K Current report
Results of operations
May 8, 2024 May 8, 2024
8-K Current report
Other events
Apr 5, 2024 Apr 5, 2024
8-K Current report
Results of operations, Regulation FD disclosure
Feb 28, 2024 Feb 28, 2024
8-K Current report
Material agreement, New debt, Unregistered share sale, Other events
Feb 2, 2024 Jan 30, 2024
8-K Current report
Results of operations, Other events
Jan 29, 2024 Jan 29, 2024
8-K Current report
Results of operations, Regulation FD disclosure, Other events
Jan 5, 2024 Jan 5, 2024
8-K Current report
Regulation FD disclosure
Jan 2, 2024 Jan 2, 2024
6-K Current report (foreign issuer) Nov 7, 2023 Nov 7, 2023
6-K Current report (foreign issuer) Aug 10, 2023 Jun 30, 2023
6-K Current report (foreign issuer) Jul 14, 2023 Jul 14, 2023
6-K Current report (foreign issuer) Jun 5, 2023 Jun 5, 2023
6-K Current report (foreign issuer) May 16, 2023 May 16, 2023
6-K Current report (foreign issuer) May 10, 2023 May 10, 2023
6-K Current report (foreign issuer) Apr 18, 2023 Apr 18, 2023
6-K Current report (foreign issuer) Apr 18, 2023 Apr 18, 2023
6-K Current report (foreign issuer) Mar 10, 2023 Mar 10, 2023
6-K Current report (foreign issuer) Mar 2, 2023 Mar 2, 2023
6-K Current report (foreign issuer) Mar 1, 2023 Mar 1, 2023
6-K Current report (foreign issuer) Feb 22, 2023 Feb 22, 2023
6-K Current report (foreign issuer) Jan 11, 2023 Jan 11, 2023
6-K Current report (foreign issuer) Jan 9, 2023 Jan 9, 2023
6-K Current report (foreign issuer) Dec 8, 2022 Dec 8, 2022
6-K Current report (foreign issuer) Dec 2, 2022 Dec 2, 2022
6-K/A Filing Nov 18, 2022 Sep 30, 2022
6-K Current report (foreign issuer) Nov 14, 2022 Nov 14, 2022
6-K Current report (foreign issuer) Nov 9, 2022 Nov 9, 2022
6-K Current report (foreign issuer) Sep 30, 2022 Sep 30, 2022
6-K Current report (foreign issuer) Sep 9, 2022 Sep 9, 2022
6-K Current report (foreign issuer) Sep 9, 2022 Sep 9, 2022
6-K Current report (foreign issuer) Aug 10, 2022 Aug 9, 2022
6-K Current report (foreign issuer) Jul 20, 2022 Jul 20, 2022
6-K Current report (foreign issuer) Jul 11, 2022 Jul 11, 2022
6-K Current report (foreign issuer) Jun 27, 2022 Jun 27, 2022
6-K Current report (foreign issuer) Jun 9, 2022 Jun 9, 2022
6-K Current report (foreign issuer) Jun 8, 2022 Jun 8, 2022
6-K Current report (foreign issuer) Jun 6, 2022 Jun 6, 2022
6-K Current report (foreign issuer) Jun 3, 2022 Jun 3, 2022
6-K Current report (foreign issuer) May 12, 2022 May 12, 2022
6-K Current report (foreign issuer) May 11, 2022 May 11, 2022
6-K Current report (foreign issuer) Apr 14, 2022 Apr 14, 2022
6-K Current report (foreign issuer) Apr 4, 2022 Apr 4, 2022
6-K Current report (foreign issuer) Mar 3, 2022 Mar 3, 2022
6-K Current report (foreign issuer) Jan 26, 2022 Jan 26, 2022
6-K Current report (foreign issuer) Dec 7, 2021 Dec 7, 2021
6-K Current report (foreign issuer) Nov 10, 2021 Nov 10, 2021
6-K Current report (foreign issuer) Aug 24, 2021 Aug 24, 2021
6-K Current report (foreign issuer) Aug 11, 2021 Aug 11, 2021
6-K Current report (foreign issuer) May 12, 2021 Mar 31, 2021

Showing 74 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
IMCR (Nasdaq)
Fiscal year ends
December 31
Incorporated in
United Kingdom
Headquarters
Oxfordshire, United Kingdom
SEC filer status
Large accelerated filer
SEC CIK
1671927
Former names
Immunocore Ltd (until Feb 1, 2021)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.